Technical Analysis for AKCA - Akcea Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 17.9 0.51% 0.09
AKCA closed up 0.51 percent on Friday, January 19, 2018, on 82 percent of normal volume. It ran into resistance at its 50 day moving average.
0 Watchers
Track This Stock
Watchlist Portfolio

Trend Table & Recent Alerts
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Up
See historical AKCA trend table...

Date Alert Name Type % Chg
Jan 19 50 DMA Resistance Bearish 0.00%
Jan 19 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Jan 19 Wide Bands Range Expansion 0.00%
Jan 19 Up 3 Days in a Row Strength 0.00%
Jan 18 MACD Bullish Signal Line Cross Bullish 0.51%
Jan 18 Wide Bands Range Expansion 0.51%
Jan 17 Wide Bands Range Expansion 3.47%
Jan 16 Wide Bands Range Expansion 9.48%
Jan 12 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 5.29%
Jan 12 Inside Day Range Contraction 5.29%

Older signals for AKCA ...

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Akcea Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing drugs to treat patients with serious cardiometabolic diseases caused by lipid disorders. The Company's drugs, volanesorsen, AKCEA-APO(a)-LRx, AKCEA-ANGPTL3-LRx and AKCEA-APOCIII-LRx, are all based on antisense technology developed by Ionis Pharmaceuticals, Inc. (Ionis). The Company's volanesorsen drug has completed a Phase III clinical program for the treatment of familial chylomicronemia syndrome (FCS) and is currently in Phase III clinical development for the treatment of familial partial lipodystrophy (FPL). The Company's clinical pipeline contains drugs with the potential to treat inadequately addressed lipid disorders beyond elevated LDL-C that are contributing to the dramatic increase in the incidence of cardiometabolic disease, such as elevated triglycerides, oxidized phospholipids and other lipoproteins, such as lipoprotein(a), or Lp(a).
Is AKCA a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 31.23
52 Week Low 8.1
Average Volume 298,849
200-Day Moving Average 0.0
50-Day Moving Average 18.0046
20-Day Moving Average 17.545
10-Day Moving Average 16.931
Average True Range 1.148
ADX 12.87
+DI 19.15
-DI 16.11
Chandelier Exit (Long, 3 ATRs ) 17.136
Chandelier Exit (Short, 3 ATRs ) 18.674
Upper Bollinger Band 19.5975
Lower Bollinger Band 15.4925
Percent B (%b) 0.59
BandWidth 23.396979
MACD Line -0.3286
MACD Signal Line -0.4394
MACD Histogram 0.1108
Fundamentals Value
Market Cap 1.14 Billion
Num Shares 63.9 Million
EPS -1.89
Price-to-Earnings (P/E) Ratio -9.47
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 19.57
Resistance 3 (R3) 19.55 18.97 19.29
Resistance 2 (R2) 18.97 18.55 18.98 19.20
Resistance 1 (R1) 18.44 18.28 18.71 18.46 19.11
Pivot Point 17.86 17.86 17.99 17.87 17.86
Support 1 (S1) 17.32 17.43 17.59 17.34 16.69
Support 2 (S2) 16.74 17.17 16.75 16.60
Support 3 (S3) 16.21 16.74 16.51
Support 4 (S4) 16.23